30 Day Trial

Xtant Medical Reports 3Q15 Revenue

Share:

Xtant Medical announced 3Q15 revenue of US $20.9MM, +6.5% from 3Q14, and YTD 2015 revenue of $64.4MM, +10.8% vs. the prior year.

For 3Q15, the company's segment revenue was Biologics $9.7MM, +15.5%; Fixation excluding OEM $10.3MM, +12.3%; OEM $0.7MM, -61%. Excluding OEM sales, 3Q15 consolidated pro forma revenue grew +13.8% to $20.2MM.

Xtant expects revenue in the range of $43MM to $46MM for 2H15, and a range of $100MM to $105MM for 2016.

Source: Xtant Medical Holdings, Inc.